HRP20161110T1 - Lapatinib za liječenje raka - Google Patents
Lapatinib za liječenje raka Download PDFInfo
- Publication number
- HRP20161110T1 HRP20161110T1 HRP20161110TT HRP20161110T HRP20161110T1 HR P20161110 T1 HRP20161110 T1 HR P20161110T1 HR P20161110T T HRP20161110T T HR P20161110TT HR P20161110 T HRP20161110 T HR P20161110T HR P20161110 T1 HRP20161110 T1 HR P20161110T1
- Authority
- HR
- Croatia
- Prior art keywords
- hla
- lapatinib
- pharmaceutically acceptable
- composition
- acceptable salt
- Prior art date
Links
- 239000002136 L01XE07 - Lapatinib Substances 0.000 title claims 16
- 229960004891 lapatinib Drugs 0.000 title claims 16
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 title claims 16
- 206010028980 Neoplasm Diseases 0.000 title claims 13
- 201000011510 cancer Diseases 0.000 title claims 13
- 150000003839 salts Chemical class 0.000 claims 15
- 238000000034 method Methods 0.000 claims 13
- 241000282414 Homo sapiens Species 0.000 claims 11
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims 10
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 claims 10
- 108010086786 HLA-DQA1 antigen Proteins 0.000 claims 10
- 108010065026 HLA-DQB1 antigen Proteins 0.000 claims 10
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 9
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 9
- 206010019851 Hepatotoxicity Diseases 0.000 claims 6
- 230000007686 hepatotoxicity Effects 0.000 claims 6
- 231100000304 hepatotoxicity Toxicity 0.000 claims 6
- 108700028369 Alleles Proteins 0.000 claims 5
- 101000626163 Homo sapiens Tenascin-X Proteins 0.000 claims 5
- 102100024549 Tenascin-X Human genes 0.000 claims 5
- 102210008409 rs12153855 Human genes 0.000 claims 5
- 102200138221 rs17207923 Human genes 0.000 claims 5
- 102000054765 polymorphisms of proteins Human genes 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 3
- 230000009916 joint effect Effects 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 238000003205 genotyping method Methods 0.000 claims 2
- 229940127084 other anti-cancer agent Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 1
- 108010058607 HLA-B Antigens Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Claims (15)
1. Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, naznačen/a time, da se upotrebljava u liječenju ljudi od raka, pri čemu navedenom čovjeku nije ustanovljeno da ima jedan ili više alelnih polimorfizama odabranih iz skupine koju čine: HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701.
2. Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, koji/koja se upotrebljava u liječenju ljudi od raka prema zahtjevu 1, naznačen/a time, da navedenom čovjeku nije utvrđeno postojanje najmanje dva polimorfizama odabrana iz skupine koju čine: HLA-DRB1*0701, HLA-DQA1*0201 i/ili HLA-DQB1*0202.
3. Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, koji/koja se upotrebljava u liječenju ljudi od raka prema zahtjevu 1 ili zahtjevu 2, naznačen/a time, da se navedeni lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, daje zajedno s najmanje jednim nekim drugim sredstvom protiv raka.
4. Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, koji/koja se upotrebljava u liječenju ljudi od raka prema zahtjevu 3, naznačen/a time, da se najmanje jedno neko drugo sredstvo protiv raka odabire iz skupine od sljedećih: trastuzumab, kapecitabin, paklitaksel, karboplatin, pazopanib i letrozol.
5. Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, naznačen/a time, da se upotrebljava u liječenju populacije ljudskih pojedinaca koji boluju od raka, pri čemu se ta populacija za liječenje odabire od početne populacije ljudskih pojedinaca koji boluju od raka, ali koja, u usporedbi s početnom populacijom ima smanjeni postotak pojedinaca s polmorfnim alelama u HLA koje su odabrane iz skupine koju čine: HLA-DQA1*0201, HLA-DQB1*0202 i HLA-DRB1*0701.
6. Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, koji/koja se upotrebljava u liječenju čovjeka koji boluje od raka, prema bilo kojem od zahtjeva 1 do 5, naznačen/a time, da navedenom čovjeku nije utvrđeno postojanje polimorfizama i/ili genotipova u TNXB kao rs12153855 i/ili rs17207923.
7. Postupak za screening ljudskog pojedinca koji boluje od raka, naznačen time, da je to pomoćni postupak kod predviđanja hepatotoksičnosti na lapatinib ili na njegovu farmaceutski prihvatljivu sol ili na njihov sastav, pri čemu taj postupak obuhvaća utvrđivanje, da li čovjek ima genotip HLA odabran iz skupine koju čine: HLA-DQA1*0201, HLA-DQB1*0202 i HLA-DRB1*0701, gdje prisutnost takvog genotipa HLA pokazuje, da je ljudski pojedinac u povećanom riziku za hepatotoksičnost na lapatinib ili na njegovu farmaceutski prihvatljivu sol ili na njihov sastav, u usporedbi s očekivanim rizikom kod opće populacije.
8. Postupak prema zahtjevu 7, naznačen time, da nadalje obuhvaća povezanost u zajedničkom djelovanju otkrivanja alele od sljedećih:
HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701 s povećanim rizikom za iskustvenu hepatotoksičnost na lapatinib ili na njegovu farmaceutski prihvatljivu sol ili na njihov sastav.
9. Postupak prema zahtjevu 7 ili zahtjevu 8, naznačen time, da nadalje obuhvaća utvrđivanje, da li navedeni pojedinac ima genotip u HLA-B*4403 i/ili u TNXB kao rs12153855 i/ili rs17207923.
10. Postupak prema bilo kojem od zahtjeva 7 do 9, naznačen time, da nadalje obuhvaća utvrđivanje, da li je navedeni pojedinac seropozitivan na DQ2.2.
11. Postupak identifikacije ljudskog pojedinca koji boluje od raka uz povećani rizik hepatotoksičnosti na terapeutski način liječenja lapatinibom ili njegovom farmaceutski prihvatljivom soli ili njihovim sastavom, naznačen time, da obuhvaća sljedeće korake:
a. izvođenje tehnike genotipizacije na biološkom uzorku od navedenog pojedinca u svrhu utvrđivanja, da li genotip HLA od ljudskog pojedinca uključuje alelu odabranu od sljedećih: HLA-DQA1*0201, HLA-DQB1*0202 ili HLA-DRB1*0701;
b. otkrivanje sljedećih: HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701; i
c. povezivanje u zajedničkom djelovanju otkrivanja sljedećih alela:
HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701, s povećanim rizikom od iskustvene hepatotoksičnosti na terapeutski sustav liječenja lapatinibom ili njegovom farmaceutski prihvatljivom soli ili njihovim sastavom, u usporedbi prema riziku kada nisu otkrivene alele od sljedećih:
HLA-DQA1*0201, HLA-DQB1*0202 i/ili HLA-DRB1*0701.
12. Postupak prema zahtjevu 11, naznačen time, da navedeni čovjek ima oba polimorfizma i HLA-DQA1*0201 i HLA-DQB1*0202.
13. Postupak prema zahtjevu 11 ili zahtjevu 12, naznačen time, da nadalje obuhvaća izvođenje tehnike genotipizacije na biološkom uzorku od navedenog ljudskog pojedinca u svrhu utvrđivanja, da li pojedinac ima genotipove u TNXB kao rs12153855 i/ili rs17207923 i povezivanje u zajedničkom djelovanju s otkrivanjem genotipa u TNXB kao rs12153855 i/ili rs17207923 s povećanim rizikom od iskustvene hepatotoksičnosti na terapeutski sustav liječenja lapatinibom ili njegovom farmaceutski prihvatljivom soli ili njihovim sastavom, u usporedbi s rizikom kada nisu otkriveni genotipovi u TNXB kao rs12153855 i/ili rs17207923.
14. Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, koji/koja se upotrebljava u liječenju čovjeka koji boluje od raka, prema bilo kojem od zahtjeva 1 do 6, ili postupak prema bilo kojem od zahtjeva 11 do 13, naznačen/a time, da je navedenom čovjeku utvrđeno, da je seropozitivan na DQ2.2.
15. Lapatinib ili njegova farmaceutski prihvatljiva sol ili njihov sastav, koji/koja se upotrebljava u liječenju čovjeka koji boluje od raka, prema bilo kojem od zahtjeva 1 do 6 ili 14, ili postupak prema bilo kojem od zahtjeva 7 do 13, naznačen/a time, da navedeni rak je rak dojke.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23594709P | 2009-08-21 | 2009-08-21 | |
| US30756910P | 2010-02-24 | 2010-02-24 | |
| PCT/US2010/046142 WO2011022633A2 (en) | 2009-08-21 | 2010-08-20 | Method of threating cancer |
| EP10810654.3A EP2467140B1 (en) | 2009-08-21 | 2010-08-20 | Lapatinib for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161110T1 true HRP20161110T1 (hr) | 2016-11-04 |
Family
ID=43607603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161110TT HRP20161110T1 (hr) | 2009-08-21 | 2016-08-30 | Lapatinib za liječenje raka |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20120156200A1 (hr) |
| EP (1) | EP2467140B1 (hr) |
| JP (1) | JP5876827B2 (hr) |
| KR (1) | KR101781658B1 (hr) |
| CN (1) | CN102770140B (hr) |
| AU (2) | AU2010284092A1 (hr) |
| BR (1) | BR112012003653A2 (hr) |
| CA (2) | CA3080511C (hr) |
| CY (1) | CY1118486T1 (hr) |
| DK (1) | DK2467140T3 (hr) |
| EA (1) | EA027959B1 (hr) |
| ES (1) | ES2589377T3 (hr) |
| HR (1) | HRP20161110T1 (hr) |
| HU (1) | HUE029098T2 (hr) |
| IL (1) | IL218230B (hr) |
| LT (1) | LT2467140T (hr) |
| ME (1) | ME02492B (hr) |
| MX (1) | MX367580B (hr) |
| PL (1) | PL2467140T3 (hr) |
| PT (1) | PT2467140T (hr) |
| RS (1) | RS55074B1 (hr) |
| SG (2) | SG178439A1 (hr) |
| SI (1) | SI2467140T1 (hr) |
| SM (1) | SMT201600296B (hr) |
| WO (1) | WO2011022633A2 (hr) |
| ZA (1) | ZA201201110B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916574B2 (en) | 2009-09-28 | 2014-12-23 | Qilu Pharmaceutical Co., Ltd. | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| KR20140117644A (ko) * | 2012-01-31 | 2014-10-07 | 스미스클라인 비이참 (코르크) 리미티드 | 암을 치료하는 방법 |
| GB201403820D0 (en) | 2014-03-04 | 2014-04-16 | Isis Innovation | Assay |
| CN104293958B (zh) * | 2014-10-16 | 2016-09-21 | 卫生部北京医院 | 一种预测强直性脊柱炎易感性的试剂盒和方法 |
| AU2017375590A1 (en) * | 2016-12-14 | 2019-06-13 | Beijing Genomics Institute At Shenzhen | Human genetic markers associated with response to treatments that target Clostridium difficile toxin B |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| EP0897567A2 (en) | 1996-04-19 | 1999-02-24 | Spectra Biomedical, Inc. | Correlating polymorphic forms with multiple phenotypes |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| JP4102185B2 (ja) | 2000-06-30 | 2008-06-18 | グラクソ グループ リミテッド | キナゾリンジトシル酸塩化合物 |
| US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
| WO2005121380A1 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham Corporation | Predictive biomarkers in cancer therapy |
| JP2007117085A (ja) * | 2005-09-28 | 2007-05-17 | Genodive Pharma Kk | 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法 |
| WO2007099852A1 (ja) | 2006-02-23 | 2007-09-07 | National University Corporation Kanazawa University | 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット |
| WO2008070448A2 (en) * | 2006-11-22 | 2008-06-12 | Board Of Regents, The University Of Texas System | Cancer-specific promoters |
| US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
| WO2008112903A2 (en) * | 2007-03-13 | 2008-09-18 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes |
-
2010
- 2010-08-20 CN CN201080047795.1A patent/CN102770140B/zh active Active
- 2010-08-20 CA CA3080511A patent/CA3080511C/en active Active
- 2010-08-20 ME MEP-2016-168A patent/ME02492B/me unknown
- 2010-08-20 JP JP2012525725A patent/JP5876827B2/ja active Active
- 2010-08-20 CA CA2771699A patent/CA2771699C/en active Active
- 2010-08-20 PT PT108106543T patent/PT2467140T/pt unknown
- 2010-08-20 PL PL10810654T patent/PL2467140T3/pl unknown
- 2010-08-20 RS RS20160681A patent/RS55074B1/sr unknown
- 2010-08-20 LT LTEP10810654.3T patent/LT2467140T/lt unknown
- 2010-08-20 KR KR1020127007152A patent/KR101781658B1/ko active IP Right Grant
- 2010-08-20 US US13/391,579 patent/US20120156200A1/en not_active Abandoned
- 2010-08-20 AU AU2010284092A patent/AU2010284092A1/en not_active Abandoned
- 2010-08-20 HU HUE10810654A patent/HUE029098T2/en unknown
- 2010-08-20 WO PCT/US2010/046142 patent/WO2011022633A2/en active Application Filing
- 2010-08-20 SG SG2012010658A patent/SG178439A1/en unknown
- 2010-08-20 EP EP10810654.3A patent/EP2467140B1/en active Active
- 2010-08-20 ES ES10810654.3T patent/ES2589377T3/es active Active
- 2010-08-20 MX MX2012002161A patent/MX367580B/es active IP Right Grant
- 2010-08-20 EA EA201270298A patent/EA027959B1/ru not_active IP Right Cessation
- 2010-08-20 SG SG10201405039VA patent/SG10201405039VA/en unknown
- 2010-08-20 DK DK10810654.3T patent/DK2467140T3/en active
- 2010-08-20 BR BR112012003653A patent/BR112012003653A2/pt not_active IP Right Cessation
- 2010-08-20 SI SI201031257A patent/SI2467140T1/sl unknown
-
2012
- 2012-02-15 ZA ZA2012/01110A patent/ZA201201110B/en unknown
- 2012-02-20 IL IL218230A patent/IL218230B/en active IP Right Grant
-
2014
- 2014-06-17 AU AU2014203270A patent/AU2014203270B2/en not_active Revoked
-
2015
- 2015-02-27 US US14/634,052 patent/US9539257B2/en active Active
-
2016
- 2016-08-30 HR HRP20161110TT patent/HRP20161110T1/hr unknown
- 2016-09-01 SM SM201600296T patent/SMT201600296B/it unknown
- 2016-09-01 CY CY20161100861T patent/CY1118486T1/el unknown
- 2016-11-21 US US15/356,719 patent/US10004742B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161110T1 (hr) | Lapatinib za liječenje raka | |
| Kiryluk et al. | Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis | |
| Gharavi et al. | Genome-wide association study identifies susceptibility loci for IgA nephropathy | |
| Alcina et al. | Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis | |
| Naumova et al. | Sex-and age-dependent DNA methylation at the 17q12-q21 locus associated with childhood asthma | |
| Peeters et al. | Clinical and genetic factors associated with sacroiliitis in Crohn's disease | |
| Smestad et al. | The impact of HLA‐A and‐DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients | |
| García-León et al. | Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients | |
| Nischwitz et al. | Risk conferring genes in multiple sclerosis | |
| Fernández et al. | Warfarin, a potential pollutant in aquatic environment acting through Pxr signaling pathway and γ-glutamyl carboxylation of vitamin K-dependent proteins | |
| WO2008137762A3 (en) | Methods of diagnosis and treatment of crohn's disease | |
| Brambila-Tapia et al. | MTHFR C677T, MTHFR A1298C, and OPG A163G polymorphisms in Mexican patients with rheumatoid arthritis and osteoporosis | |
| WO2013056087A3 (en) | Compositions and methods for treating and preventing coronary heart disease | |
| MX2011008323A (es) | Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal. | |
| WO2010060996A3 (en) | Prediction of lipid-metabotype-related physiological susceptibilities | |
| Qian et al. | Association of STAT6 variants with asthma risk: a systematic review and meta-analysis | |
| Freudenberger et al. | Genetics of age-related white matter lesions from linkage to genome wide association studies | |
| WO2010103292A3 (en) | A genotyping tool for improving the prognostic and clinical management of ms patients | |
| Rusmini et al. | How genetics might explain the unusual link between malaria and COVID-19 | |
| MX2017011910A (es) | Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2. | |
| Jern et al. | Serotonergic polymorphisms in the control of ejaculation | |
| JP2013502433A5 (hr) | ||
| Xie et al. | Association between genetic variations of NMDA receptor NR3 subfamily genes and heroin addiction in male Han Chinese | |
| EP4296285A3 (en) | Methods and systems for selection and treatment of patients with inflammatory diseases | |
| Sebib Korkmaz et al. | MMP‐2 is a disease‐modifying gene in primary sclerosing cholangitis |